Cerebrolysin
Also known as: FPE 1070
Key Facts: Cerebrolysin
- Category
- Cognitive
- FDA Status
- Not FDA Approved
- Clinical Status
- Approved in 40+ countries - Not FDA approved
- Administration
- Intravenous or intramuscular injection
- Typical Dose
- 5-10 ml IV/IM daily for 10-20 days
- Frequency
- Daily during treatment cycles
- Evidence Level
- Human Trials
- Duration
- 10-20 day cycles
What to Expect
A mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
Mechanism of Action
Cerebrolysin contains neurotrophic factors that mimic BDNF, NGF, and CNTF activity. It enhances neuroplasticity, protects neurons from excitotoxicity, promotes neurogenesis, and improves synaptic function.
Research Summary
Approved in over 40 countries for neurological conditions. Studies show benefits in stroke recovery, Alzheimer's disease, and TBI. Large clinical trials demonstrate improved cognitive function and activities of daily living.
Dosing Information
Typical Dosingⓘ
Community experience
5-10 ml IV/IM daily for 10-20 days
5-30 ml per day
Daily during treatment cycles
Neuropeptide mixture requiring injection. Used in cycles. Approved in some countries for cognitive disorders.
Research Dosingⓘ
Scientific studies
Doses from clinical practice
Doses from Studies
10-30 mL daily IV for acute conditions
5-10 mL IM for maintenance
Duration
10-20 day cycles
Administration
Intravenous or intramuscular injection
Timing & Administration
Best Time to Take
Morning
Once daily, often in cycles
Food Recommendation
With or without food
Why This Timing?
Cerebrolysin supports cognitive function. Morning use aligns with peak cognitive demands.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Dizziness
- ●Headache
- ●Nausea
- ●Agitation
- ●Confusion
- ●Anaphylactic shock (rare)
- ●Not FDA approved in US
References
Related Peptides
Peptides commonly compared with Cerebrolysin or used in similar applications.
Selank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveSemax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
CognitiveDihexa
PreclinicalA potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
CognitiveGB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia and currently in clinical trials for anxiety and cognitive enhancement. Users report significant improvements in focus, attention, and ADHD-like symptoms.
CognitiveP21
PreclinicalA synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.
CognitiveARA-290
Clinical TrialsAn 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
CognitiveWant updates on Cerebrolysin research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.